Roughly 10–20% of the invasive breast cancers1, 2 are triple negative breast cancers (TNBCs), i.e., they lack estrogen receptor (ER), progesterone receptor (PR) and do not overexpress human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to triple-negative breast carcinoma.